Indian generic shipments seized by Dutch; Pfizer spent $6.1M lobbying in Q1;

> Even after India raised concerns with EU officials, its generics companies continue to see their drug shipments hung up in--even seized by--Dutch customs. Report

> Pfizer spent more than $6.1 million lobbying the government in the first quarter on health care reform, drug coverage provided under various government programs and other matters, according to a recent disclosure. Report

> Endo Pharmaceuticals granted Valeant Pharmaceuticals an exclusive license to market the pain drug Opana in Canada, Australia and New Zealand for an upfront payment of C$2 million ($1.8 million). Report

> Astellas Pharma, Japan's second-largest drugmaker, plans to retire 28 million treasury shares later this month, and to increase its annual stock dividend by 5 yen in fiscal 2009, the Nikkei business daily said. Report

> A businessman who made a multi-million pound fortune from selling fake and unlicensed Viagra-style drugs on the internet is facing a new life in jail. Report

> MDRNA said the FDA approved its version of the Novartis nasal spray Miacalcin used to treat osteoporosis, adding that its partner Par Pharmaceutical had launched the product. Report

> Sinovac Biotech, a vaccine-focused company in China, started efforts to manufacture A/H1N1 influenza vaccine for human use on Monday, after it received the flu strain samples from the WHO, reported Beijing News. Report

> DxNA said it has submitted a request to the FDA for Emergency Use Authorization (EUA) for its GeneSTAT pathogen platform, for the detection of the H1N1 virus. Release

> FDA warned consumers not to use skin products--including hand sanitizer--made by Clarcon because of high levels of disease-causing bacteria found during a recent inspection. Report

Biotech News

> Faced with a perfect political storm brought on by low poll numbers and declining tax revenue, New York Gov. David Paterson has come up with a novel plan aimed at ginning some big bucks for biomedical research. The governor is setting aside $100 million for research institutions in the state, and he wants to leverage each dime in that budget for $1 in federal stimulus money. Report

> Wooed by a new and potentially revolutionary approach to developing drugs, the venture arms of four of the world's biggest pharma companies have joined forces to back Aileron Therapeutics in a $40 million venture round. Report

> Australian vaccine maker CSL and Talecris Biotherapeutics have called a halt to a proposed $3.1 billion merger after running straight into a posse of U.S. antitrust regulators. Report

> With a blockbuster diabetes franchise hanging in the balance, Novo Nordisk touted new data over the weekend that shows its experimental therapy liraglutide bested a standard therapy after two years of dosing. Report

> Shares of Lundbeck took a bad hit this morning after the Copenhagen-based developer revealed that its experimental depression drug LuAA21004 failed to beat out a placebo at a low dose. Lundbeck report

IT News

> This is the time to negotiate steep discounts for traditional on-premise software, according to 60 percent of respondents to an IDC survey. Report

> 23andMe is one of nearly 100 companies worldwide that genetics services, and one of few that also let customers create a public profile and share their genetic data. Such data, however, necessarily applies to multiple people. And bioethicists advise that sharing genetic information online raises a host of ethical questions, including issues of privacy and consent. Report

Research News

> The Max Planck Society has recruited a Nobel Prize-winning scientist to become the science director of its new research center in Palm Beach County, Florida. Report

> Scientists exploring ways to significantly increase our longevity have been focused on the insulin-signaling pathway. Deactivating a gene in the pathway can extend the lives of animals, probably for the same reasons that extreme low-calorie diets produce a similar effect, reports the New York Times. Report

And Finally... Greek wholesalers have guaranteed their national drugs supply chain is counterfeit-free as they fight against big pharma's direct-to-pharmacy delivery models. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.